YYYH yields 222222.22% · ABBV yields 3.06%● Live data
📍 YYYH pulled ahead of the other in Year 1
Combined, YYYH + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YYYH + ABBV for your $10,000?
China Yanyuan Yuhui Natl Ed Group Inc., a digital advertising technology company, develops and provides advertising software and service solutions in the United States. It operates an advertising technology platform, the MediaShift Monetization Platform, which deploys digital advertisements on WiFi networks at sign-in and while surfing the Internet through display ads and interstitial videos. Its target market comprises network providers offering Internet access to individual and business viewers; and Internet service providers, multiple system operators, and higher education venues with a fixed end-user base to airports, convention centers, hotels, coffee shops, and other venues. The company also operates EducationShift, which focuses on developments in journalism education and MetricShift, which provides content on metrics and analytics and measures impact through original reporting, aggregation, and audience engagement and community. The company sells its products and services directly, as well as through resellers. The company was formerly known as MediaShift, Inc. China Yanyuan Yuhui Natl Ed Group Inc. was founded in 2006 and is based in Oceanside, New York.
Full YYYH Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.